MeSH tree: E01.789.800.285
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery ...
Feb 27, 2026
0
7
A study by investigators from Mass General Brigham Cancer Institute evaluates the efficacy and safety of proton therapy for patients with lower grade gliomas (LGGs). The single-arm prospective phase 2 trial results demonstrated ...
Feb 11, 2026
0
10
New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival ...
Feb 9, 2026
0
15
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved ...
Feb 2, 2026
0
6
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease progression than patients receiving treatment later in the day. The findings, published as part of a randomized ...
Feb 2, 2026
0
39
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly ...
Jan 22, 2026
0
14
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
12
For patients with human epidermal growth factor receptor 2-positive (HER2-positive) metastatic or locally advanced unresected gastroesophageal adenocarcinoma (mGEA), zanidatamab and chemotherapy, with or without tislelizumab, ...
Jan 12, 2026
0
8
Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small ...
Sep 7, 2025
0
36
The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated Hominenteromicrobium strain YB328, mobilizes specialized dendritic cells to strengthen the impact of PD-1 blockade ...
